evipedia.ai ← Back to Review

Audit: QRS - Piceatannol for Health & Longevity

Audit conducted on 26/06/2026 02:38 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 86
Failed 0
N/A 5
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All QRS content traces to the ER (protocol, benefits, risks, monitoring, interactions).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious framing preserved (e.g., “limited safety data”, “no timing study exists”).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications and speculative tiers kept at ER’s strength.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications/interactions drawn from ER “Key Interactions & Contraindications”; categories preserved.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 QRS introduces no citations, PMIDs, NCT IDs, or brand names.
1.6 The QRS does not introduce new attributions. 🟢 No new attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Objective, evidence-strength framing matches the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Expert yet accessible throughout.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not directives.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No prescriptive advice; footer disclaimer present.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information presented, not recommended.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain language used; technical terms minimized.
2.8 Information is presented in a concise and very compact manner 🟢 Compact cells and bullets throughout.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing fits a proactive longevity audience.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring detail assumes a willing audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not written for the general population.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Weighting matches audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. 🟢 No “anti-aging” language; “Health & Longevity” framing.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. 🟢 Formal terminology used (e.g., “supplement”, “oral dose”).

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); gate headings (“Contraindications”, “Key Interactions”); tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring table column headers (“Marker”, “Target”, “Why”). 🟢 All fixed labels/headings intact.
3.2 All “…” from the [qrs_template] are present in the QRS. 🟢 All template spans present; repeatable marker/qualitative spans correctly expanded.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Unaddressed spans unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. 🟢 Empty benefit/risk tiers handled via display:none per 12.5/13.5; no empty-state phrasing required.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Labels (e.g., “Standard Dose”, marker names) match ER.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels faithful to ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). 🟢 No emoji indicators in QRS body.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to fit one page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment immediately follows doctype (lines 2-14).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. 🟢 YAML delimited by “—” at lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Values clean; only duration quoted (contains colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]”. 🟢 er_filename: piceatannol_2026-0626-0156_Opus_ER.md (line 4).
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. 🟢 qrs_prompt_version: 26.5.18 (line 5).
5.7 Creation date and time stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. 🟢 qrs_creation_date: 2026-0626-0156 (line 6).
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname”. 🟢 qrs_creator_ai_nickname: Opus (line 7).
5.9 The nickname of the AI is just a single word model name without version. 🟢 “Opus” is single-word.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname”. 🟢 qrs_creator_ai_fullname: Opus 4.8 (line 8).
5.11 The full name consists of nickname plus model version number and no additional qualifier. 🟢 “Opus 4.8” correct.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]”. 🟢 qrs_filename: piceatannol_2026-0626-0156_Opus_QRS.html (line 9).
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless required by YAML. 🟢 Frontmatter clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. 🟢 “Piceatannol for Health & Longevity - Quick Reference Sheet” (line 22).
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. 🟢 “Piceatannol for Health & Longevity” (line 417).
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. 🟢 “06/26/2026” (line 421).
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname]. 🟢 “Opus 4.8” (line 425).
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only title and standard subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. 🟢 Distills the ER Conclusion (lines 399-401).
7.2 [at_a_glance] is no longer than 60 words. 🟢 53 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Resveratrol relation, passion-fruit source, insulin in overweight men, skin, rapid clearance, tolerability, early-stage — all in ER.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge. 🟢 Plain-language only.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values). 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results. 🟢 No statistics.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section. 🟢 Derived from ER line 273 “Populations who should avoid”.
8.2 [stop_items] represent the Contraindications from the ER. 🟢 Pregnancy/breastfeeding, bleeding/surgery, anticoagulants w/o supervision, hormone-sensitive cancers.
8.3 Individual [stop_items] are formatted as <li></li>. 🟢 Each item is an <li> (lines 542-545).
8.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after an em/en/hyphen-dash. 🟢 Concise, no trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept concise. 🟢 “within ~2 weeks” time window preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase, normalize to a plain comma-separated list. 🟢 No ranking notation present; items are plain lists.
8.7 If no [stop_items] are present the section is left empty. N/A stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section. 🟢 Derived from ER lines 263-271.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications. 🟢 Five interactions; none duplicated from contraindications.
9.3 Individual [caution_items] are formatted as <li></li>. 🟢 Each item is an <li> (lines 553-557).
9.4 Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details, or content after an em/en/hyphen-dash. 🟢 Concise; no trailing clauses.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. 🟢 Example drug lists preserved in parens.
9.6 When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. 🟢 No ranking notation; plain comma lists.
9.7 If no [caution_items] are present the section is left empty. N/A caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section. 🟢 Derived from ER Therapeutic Protocol (lines 289-311).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. 🟢 Standard dose, dosing pattern, best time of day.
10.3 If less than three distinct actionable aspects are mentioned, unused sets are left empty and invisible, not filled with placeholders. N/A Three distinct aspects present and used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 20 mg/day, once daily, with a meal — all ER-supported.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER. 🟢 Metabolic markers (8 wk), SIRT1 (2 wk), skin (over weeks).
11.2 The sets are picked and ordered by the magnitude of the related benefit. 🟢 Metabolic (primary documented benefit) first, then SIRT1, then skin.
11.3 If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and invisible, not filled with placeholders. N/A Three distinct aspects present and used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 8 weeks, 2 weeks, over weeks — ER-supported (lines 159, 340).
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section. 🟢 Derived from ER Expected Benefits (lines 135-190).
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. 🟢 All four present.
12.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Low and speculative items concise.
12.4 Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. 🟢 No parentheticals carried over.
12.5 If no items of a sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. 🟢 High and Medium empty and set display:none (lines 521-526).

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section. 🟢 Derived from ER Potential Risks (lines 206-245).
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. 🟢 All four present.
13.3 Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. 🟢 Low and speculative items concise.
13.4 Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. 🟢 No parentheticals carried over.
13.5 If no items of a sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. 🟢 High and Medium empty and set display:none (lines 569-573).

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section. 🟢 Derived from ER Monitoring Protocol (lines 360-374).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed. 🟢 All 7 ER biomarkers present with matching targets.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 “Baseline, then around 8–12 weeks, then every 6–12 months” matches ER line 364.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section. 🟢 Derived from ER qualitative markers (lines 376-381).
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed. 🟢 All four qualitative markers present (lines 685-696).

Issues 26/06/2026 02:38

Pass rate 100.00%. No issues found.

Issues 26/06/2026 02:34

  1. 11.2 — Time-to-effect ordering by magnitude: The Time to Effect cells are ordered metabolic markers, skin outcomes, SIRT1 expression, but the ER Expected Benefits Low tier lists insulin sensitivity → SIRT1 → skin; SIRT1 and skin should be transposed to follow benefit magnitude.

Fixes 26/06/2026 02:34

  1. 11.2 — Time-to-effect ordering by magnitude: Transposed the second and third Time to Effect cells so the order now follows benefit magnitude — Metabolic Markers (8 weeks), SIRT1 Expression (2 weeks), Skin Outcomes (over weeks) — matching the ER Expected Benefits Low-tier order.